Financial Contrast: Dianthus Therapeutics (NASDAQ:DNTH) vs. Spruce Biosciences (NASDAQ:SPRB)

Spruce Biosciences (NASDAQ:SPRB) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Earnings and Valuation

This table compares Spruce Biosciences and Dianthus Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91 million	29.22	-$38.97 million	($39.78)	-1.26
Dianthus Therapeutics	$2.04 million	2,641.95	-$162.34 million	($4.15)	-23.70

Spruce Biosciences has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Spruce Biosciences and Dianthus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Insider & Institutional Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Spruce Biosciences has a beta of 3.31, indicating that its share price is 231% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Spruce Biosciences and Dianthus Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1	1	11	0	2.77
Dianthus Therapeutics	1	0	13	1	2.93

Spruce Biosciences currently has a consensus target price of $158.33, suggesting a potential upside of 216.73%. Dianthus Therapeutics has a consensus target price of $129.83, suggesting a potential upside of 32.01%. Given Spruce Biosciences’ higher probable upside, equities research analysts clearly believe Spruce Biosciences is more favorable than Dianthus Therapeutics.

Summary

Spruce Biosciences beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.